<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NARATRIPTAN - naratriptan hydrochloride tablet </strong><br>Heritage Pharmaceuticals Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">FULL PRESCRIBING INFORMATION</span><br>These highlights do not include all the information needed to use Naratriptan safely and effectively. See full prescribing information for Naratriptan.<br><br>Naratriptan (Naratriptan) TABLET for ORAL use.  <br> Rx only <br>Initial U.S. Approval: 1998</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta"> Naratriptan Tablets, USP is a serotonin (5-HT<span class="Sub">1B/1D</span>) receptor agonist (triptan) indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults. (1)  (<a href="#section-1">1</a>)</p>
<p class="Highlighta"><span class="Underline"> Limitations of Use:</span>  (<a href="#section-1">1</a>)</p>
<ul>
<li> Use only if a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has been established. (1)</li>
<li> Not indicated for the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. (1)</li>
<li> Not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span>. (1)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li> Recommended dose: 1 mg or 2.5 mg. (2.1)</li>
<li> May repeat dose after 4 hours if needed; not to exceed 5 mg in any 24- hour period. (2.1)</li>
<li> Mild or moderate renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>: recommended starting dose is 1 mg not to exceed 2.5 mg in any 24-hour period. (2.2, 2.3)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta"> Tablets: 1 mg and 2.5 mg (3, 16)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li> History of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> (4)</li>
<li> Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders (4)</li>
<li> History of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack, or hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (4)</li>
<li> <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span> (4)</li>
<li> Ischemic bowel disease (4)</li>
<li> <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> (4)</li>
<li> Recent (within 24 hours) use of another 5-HT<span class="Sub">1</span> agonist (e.g., another triptan) or an ergotamine-containing medication (4)</li>
<li> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to naratriptan tablets, USP (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> seen) (4)</li>
<li> Severe renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (4)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li> <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial ischemia</span>/<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> and Prinzmetal’s angina: Perform cardiac evaluation in patients with multiple cardiovascular risk factors. (5.1)</li>
<li> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>: Discontinue naratriptan tablets, USP if occurs. (5.2</li>
<li> Chest/throat/neck/<span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>, tightness, pressure, or heaviness: Generally not associated with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>; evaluate for CAD in patients at high risk. (5.3)</li>
<li> <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>: Discontinue naratriptan tablets, USP if occurs. (5.4)</li>
<li> Gastrointestinal ischemic reactions and peripheral vasospastic reactions: Discontinue naratriptan tablets, USP if occurs. (5.5)</li>
<li> Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>: Detoxification may be necessary. (5.6)</li>
<li> <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span>: Discontinue naratriptan tablets, USP if occurs. (5.7)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"> Most common adverse reactions (≥2% and &gt;placebo) were <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and throat/neck symptoms. (6.1)  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Heritage Pharmaceuticals Inc. at 1-866-901-3784 and <span class="Bold">www.heritagepharma.com</span> or FDA at 1-800-FDA-1088 or <span class="Bold Italics">www.fda.gov/medwatch.</span></span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta"> Pregnancy: Based on animal data, may cause fetal harm. (8.1)  (<a href="#section-8">8</a>)</p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1  INDICATIONS &amp; USAGE 
</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2  DOSAGE &amp; ADMINISTRATION 
</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold Italics">2.1	Dosing Information
</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold Italics">2.2	Dosage Adjustment in Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold Italics">2.3	Dosage Adjustment in Patients With <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3  DOSAGE FORMS &amp; STRENGTHS 
</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4  CONTRAINDICATIONS 
</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5  WARNINGS AND PRECAUTIONS 
</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold Italics">5.1	<span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and Prinzmetal’s Angina
</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold Italics">5.2	<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>
</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold Italics">5.3 Chest, Throat, Neck, and/or <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure
</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold Italics">5.4 Cerebrovascular Events
</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold Italics">5.5 Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions
</span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold Italics">5.6 Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> 
</span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold Italics">5.7 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>
</span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold Italics">5.8 Increase in Blood Pressure 
</span></a></h2>
<h2><a href="#section-5.9" class="toc"><span class="Bold Italics">5.9 Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span>
</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6  ADVERSE REACTIONS 
</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold Italics">6.1 Clinical Trials Experience
</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7  DRUG INTERACTIONS 
</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold Italics">7.1 Ergot-Containing Drugs
</span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold Italics">7.2 Other 5-HT<span class="Sub">1 </span>Agonists
</span></a></h2>
<h2><a href="#section-7.3" class="toc"><span class="Bold Italics">7.3 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>
</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8  USE IN SPECIFIC POPULATIONS 
</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold Italics">8.1  PREGNANCY 
</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold Italics"> 8.3  NURSING MOTHERS 
</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold Italics"> 8.4  PEDIATRIC USE 
</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold Italics">8.5  GERIATRIC USE 
</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold Italics">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</span></a></h2>
<h2><a href="#section-8.6" class="toc"><span class="Bold Italics">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10  OVERDOSAGE 
</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11  DESCRIPTION 
</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12  CLINICAL PHARMACOLOGY 
</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold Italics"> 12.1  MECHANISM OF ACTION 
</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold Italics"> 12.2  PHARMACODYNAMICS 
</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold Italics"> 12.3  PHARMACOKINETICS 
</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13  NONCLINICAL TOXICOLOGY 
</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold Italics"> 13.1  CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY 
</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14  CLINICAL STUDIES 
</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16  HOW SUPPLIED /STORAGE AND HANDLING 
</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17  PATIENT COUNSELING INFORMATION 
</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1><span class="Bold">1  INDICATIONS &amp; USAGE 
</span></h1>
<p class="First"></p>
<p></p>
<p>Naratriptan tablets, USP are indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults.</p>
<p><span class="Underline">Limitations of Use:</span></p>
<ul class="Disc">
<li>Use only if a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has been established. If a patient has no response to the first <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack treated with naratriptan tablets, reconsider the diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> before naratriptan tablets is administered to treat any subsequent attacks.</li>
<li>Naratriptan tablets, USP are not indicated for the prevention of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks.</li>
<li>Safety and effectiveness of naratriptan tablets, USP have not been established for <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1><span class="Bold">2  DOSAGE &amp; ADMINISTRATION 
</span></h1>
<div class="Section">
<a name="section-2.1"></a><p></p>
<h2><span class="Bold Italics">2.1	Dosing Information
</span></h2>
<p class="First">The recommended dose of naratriptan tablets, USP is 1 mg or 2.5 mg.</p>
<p>If the <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> returns or if the patient has only partial response, the dose may be repeated once after 4 hours, for a maximum dose of 5 mg in a 24-hour period.</p>
<p>The safety of treating an average of more than 4 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks in a 30-day period has not been established.</p>
</div>
<div class="Section">
<a name="section-2.2"></a><p></p>
<h2><span class="Bold Italics">2.2	Dosage Adjustment in Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</span></h2>
<p class="First">Naratriptan tablets, USP is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance: &lt;15 mL/min) because of decreased clearance of the drug [see <span class="Italics"><a href="#b19ca367-6d7c-4139-931a-e90635c34161">Contraindications (4)</a></span>, <span class="Italics"><a href="#b2d7fb9d-572a-4827-8ce0-a4d324f8987a">Use in Specific Populations (8.6)</a></span>, <span class="Italics"><a href="#b9049735-f40c-4327-a642-7d1bd7fefcc6">Clinical Pharmacology (12.3)</a></span>].</p>
<p>In patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the maximum daily dose should not exceed 2.5 mg over a 24-hour period and a 1-mg starting dose is recommended [see <span class="Italics"><a href="#b2d7fb9d-572a-4827-8ce0-a4d324f8987a">Use in Specific Populations (8.6)</a></span>, <span class="Italics"><a href="#b9049735-f40c-4327-a642-7d1bd7fefcc6">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section">
<a name="section-2.3"></a><p></p>
<h2><span class="Bold Italics">2.3	Dosage Adjustment in Patients With <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</span></h2>
<p class="First">Naratriptan tablets, USP are contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh grade C) because of decreased clearance [see <span class="Italics"><a href="#b19ca367-6d7c-4139-931a-e90635c34161">Contraindications (4)</a></span>, <span class="Italics"><a href="#b7691efe-5637-487c-bea4-f09e12a9ead0">Use in Specific Populations (8.7)</a></span>, <span class="Italics"><a href="#b9049735-f40c-4327-a642-7d1bd7fefcc6">Clinical Pharmacology (12.3)</a></span>].</p>
<p>In patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh grade A or B), the maximum daily dose should not exceed 2.5 mg over a 24-hour period and a 1-mg starting dose is recommended [see <span class="Italics"><a href="#b7691efe-5637-487c-bea4-f09e12a9ead0">Use in Specific Populations (8.7)</a></span>, <span class="Italics"><a href="#b9049735-f40c-4327-a642-7d1bd7fefcc6">Clinical Pharmacology (12.3)</a></span>].</p>
<p><a name="bf8befc8-2137-47bc-850e-e048bdf234e2"></a></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1><span class="Bold">3  DOSAGE FORMS &amp; STRENGTHS 
</span></h1>
<p class="First"></p>
<p>1-mg yellow, round, biconvex film-coated tablets, debossed with ‘I53’</p>
<p>2.5-mg white, ‘D’ shaped, biconvex film-coated tablets, debossed with ‘I54’</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="b19ca367-6d7c-4139-931a-e90635c34161"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">4  CONTRAINDICATIONS 
</span></h1>
<p class="First">Naratriptan tablets, USP are contraindicated in patients with:</p>
<ul class="Disc">
<li>Ischemic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD) (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or documented silent <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>) or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, including Prinzmetal’s angina [see <span class="Italics"><a href="#b178a942-f9f3-409c-8826-4d3d6ada91f2">Warnings and Precautions (5.1)</a></span>]</li>
<li>Wolff-Parkinson-White syndrome or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> associated with other cardiac accessory conduction pathway disorders [see <span class="Italics"><a href="#b92bb827-1e62-4915-9920-0c0c75c3fd6f">Warnings and Precautions (5.2)</a></span>]</li>
<li>History of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or transient ischemic attack (TIA) or history of hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> because such patients are at a higher risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> [see <span class="Italics"><a href="#b477b4a3-a624-4ecc-a504-d4a52f32a200">Warnings and Precautions (5.4)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span> [see <span class="Italics"><a href="#ba82435c-f7a4-4876-87c0-e8acddb8df10">Warnings and Precautions (5.5)</a></span>]</li>
<li>Ischemic bowel disease [see <span class="Italics"><a href="#ba82435c-f7a4-4876-87c0-e8acddb8df10">Warnings and Precautions (5.5)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> [see <span class="Italics"><a href="#bab64407-a967-4fa2-9549-5f3dcf3c42ca">Warnings and Precautions (5.8)</a></span>]</li>
<li>Recent use (i.e., within 24 hours) of another 5-HT<span class="Sub">1</span> agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see <span class="Italics"><a href="#b9c1a35b-5fb2-4abd-8884-901fac861899">Drug Interactions</a></span> (7.1, 7.2)]</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to naratriptan tablets, USP (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> seen) [see<span class="Italics"><a href="#b8e9d1d1-9d7b-45b9-896a-b3da3bc6b9f0">Warnings and Precautions </a></span>(5.9)]</li>
<li>Severe renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Italics"><a href="#bc7cbcc7-be82-427b-9308-d62c1d42b6ca">Use in Specific Populations</a></span> (8.6, 8.7), <span class="Italics"><a href="#b9049735-f40c-4327-a642-7d1bd7fefcc6">Clinical Pharmacology </a></span>(12.3)]</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="b02e42e6-f8fd-4d3b-8fb0-6ad65cf7a731"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">5  WARNINGS AND PRECAUTIONS 
</span></h1>
<ul class="Disc"><li>)</li></ul>
<div class="Section">
<a name="b178a942-f9f3-409c-8826-4d3d6ada91f2"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold Italics">5.1	<span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and Prinzmetal’s Angina
</span></h2>
<p class="First">Naratriptan tablets are contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, occurring within a few hours following administration of naratriptan tablets. Some of these reactions occurred in patients without known CAD. Naratriptan tablets may cause coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> (Prinzmetal’s angina), even in patients without a history of CAD.</p>
<p>Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, strong family history of CAD) prior to receiving naratriptan tablets. If there is evidence of CAD or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, naratriptan tablets are contraindicated. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administering the first dose of naratriptan tablets in a medically supervised setting and performing an electrocardiogram (ECG) immediately following administration of naratriptan tablets. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of naratriptan tablets.</p>
</div>
<div class="Section">
<a name="b92bb827-1e62-4915-9920-0c0c75c3fd6f"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold Italics">5.2	<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>
</span></h2>
<p class="First">Life-threatening disturbances of cardiac rhythm, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported within a few hours following the administration of 5-HT<span class="Sub">1</span> agonists. Discontinue naratriptan tablets if these disturbances occur. Naratriptan tablets are contraindicated in patients with Wolff-Parkinson-White syndrome or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> associated with other cardiac accessory conduction pathway disorders.</p>
</div>
<div class="Section">
<a name="b96a6772-f88c-4caf-8deb-4920c4fc94cd"></a><a name="section-5.3"></a><p></p>
<h2><span class="Bold Italics">5.3 Chest, Throat, Neck, and/or <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure
</span></h2>
<p class="First">Sensations of tightness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and pressure in the chest, throat, neck, and jaw commonly occur after treatment with naratriptan tablets and are usually non-cardiac in origin. However, perform a cardiac evaluation if these patients are at high cardiac risk. 5-HT<span class="Sub">1</span> agonists, including naratriptan tablets, are contraindicated in patients with CAD and those with Prinzmetal’s <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span>.</p>
</div>
<div class="Section">
<a name="b477b4a3-a624-4ecc-a504-d4a52f32a200"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold Italics">5.4 Cerebrovascular Events
</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> have occurred in patients treated with 5-HT<span class="Sub">1</span> agonists, and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the 5-HT<span class="Sub">1</span> agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> when they were not. Also, patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> may be at increased risk of certain cerebrovascular events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, TIA). Discontinue naratriptan tablets if a cerebrovascular event occurs.</p>
<p>Before treating <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> in patients not previously diagnosed as migraineurs, and in migraineurs who present with symptoms atypical for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, exclude other potentially serious neurological conditions. Naratriptan tablets are contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA.</p>
</div>
<div class="Section">
<a name="ba82435c-f7a4-4876-87c0-e8acddb8df10"></a><a name="section-5.5"></a><p></p>
<h2><span class="Bold Italics">5.5 Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions
</span></h2>
<p class="First">Naratriptan tablets may cause non-coronary vasospastic reactions, such as peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, gastrointestinal vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> (presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>), <span class="product-label-link" type="condition" conceptid="4044745" conceptname="Splenic infarction">splenic infarction</span>, and Raynaud’s syndrome. In patients who experience symptoms or signs suggestive of non-<span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary vasospasm</span> reaction following the use of any 5-HT<span class="Sub">1 </span>agonist, rule out a vasospastic reaction before receiving additional doses of naratriptan tablets.</p>
<p>Reports of transient and permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> and significant partial <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span> have been reported with the use of 5-HT<span class="Sub">1</span> agonists. Since visual disorders may be part of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack, a causal relationship between these events and the use of 5-HT<span class="Sub">1</span> agonists have not been clearly established.</p>
</div>
<div class="Section">
<a name="b3ae15d0-095c-44c0-9170-bd5664ef96a1"></a><a name="section-5.6"></a><p></p>
<h2><span class="Bold Italics">5.6 Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> 
</span></h2>
<p class="First">Overuse of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> drugs (e.g., ergotamine, triptans, opioids, or combination of these drugs for 10 or more days per month) may lead to exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>). Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> may present as <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-like daily <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> or as a marked increase in frequency of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms (which often includes a transient worsening of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>) may be necessary.</p>
</div>
<div class="Section">
<a name="bcd2888d-39fa-4564-a766-f7f2fed08911"></a><a name="section-5.7"></a><p></p>
<h2><span class="Bold Italics">5.7 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>
</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> may occur with naratriptan tablets, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase (MAO) inhibitors [see Drug Interactions (7.3)]. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue naratriptan tablets if <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> is suspected.</p>
</div>
<div class="Section">
<a name="bab64407-a967-4fa2-9549-5f3dcf3c42ca"></a><a name="section-5.8"></a><p></p>
<h2><span class="Bold Italics">5.8 Increase in Blood Pressure 
</span></h2>
<p class="First">Significant elevation in blood pressure, including <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span> with acute impairment of organ systems, has been reported on rare occasions in patients treated with 5-HT<span class="Sub">1</span> agonists, including patients without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Monitor blood pressure in patients treated with naratriptan tablets. Naratriptan tablets are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>.</p>
</div>
<div class="Section">
<a name="b8e9d1d1-9d7b-45b9-896a-b3da3bc6b9f0"></a><a name="section-5.9"></a><p></p>
<h2><span class="Bold Italics">5.9 Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span>
</span></h2>
<p class="First">There have been reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and anaphylactoid and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, in patients receiving naratriptan tablets. Such reactions can be life threatening or fatal. In general, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens. Naratriptan tablets are contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to naratriptan tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1><span class="Bold">6  ADVERSE REACTIONS 
</span></h1>
<p class="First"></p>
<p>The following adverse reactions are discussed in more detail in other sections of the prescribing information:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and Prinzmetal’s angina [see <span class="Italics"><a href="#b178a942-f9f3-409c-8826-4d3d6ada91f2">Warnings and Precautions (5.1</a></span>)]</li>
<li><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> [see <span class="Italics"><a href="#b92bb827-1e62-4915-9920-0c0c75c3fd6f">Warnings and Precautions (5.2)</a></span>]</li>
<li>Chest, throat, neck, and/or <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>/tightness/pressure [see <span class="Italics"><a href="#b96a6772-f88c-4caf-8deb-4920c4fc94cd">Warnings and Precautions (5.3)</a></span>]</li>
<li>Cerebrovascular events [see <span class="Italics"><a href="#b477b4a3-a624-4ecc-a504-d4a52f32a200">Warnings and Precautions (5.4)</a></span>]</li>
<li>Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> reactions [see <span class="Italics"><a href="#ba82435c-f7a4-4876-87c0-e8acddb8df10">Warnings and Precautions (5.5)</a></span>]</li>
<li>Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> [see <span class="Italics"><a href="#b3ae15d0-095c-44c0-9170-bd5664ef96a1">Warnings and Precautions (5.6)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> [see <span class="Italics"><a href="#bcd2888d-39fa-4564-a766-f7f2fed08911">Warnings and Precautions (5.7)</a></span>]</li>
<li>Increase in blood pressure [see <span class="Italics"><a href="#bab64407-a967-4fa2-9549-5f3dcf3c42ca">Warnings and Precautions (5.8)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> [see <span class="Italics"><a href="#b19ca367-6d7c-4139-931a-e90635c34161">Contraindications (4)</a>, <a href="#b8e9d1d1-9d7b-45b9-896a-b3da3bc6b9f0">Warnings and Precautions (5.9)</a></span>]</li>
</ul>
<div class="Section">
<a name="section-6.1"></a><p></p>
<h2><span class="Bold Italics">6.1 Clinical Trials Experience
</span></h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>In a long-term open-label trial where patients were allowed to treat multiple <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks for up to 1 year, 15 patients (3.6%) discontinued treatment due to adverse reactions.</p>
<p>In controlled clinical trials, the most common adverse reactions were <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and throat/neck symptoms, which occurred at a rate of 2% and at least 2 times placebo rate.</p>
<p>Table 1 lists the adverse reactions that occurred in 5 placebo-controlled clinical trials of approximately 1,752 exposures to placebo and naratriptan tablets in adult patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. Only reactions that occurred at a frequency of 2% or more in groups treated with naratriptan tablets 2.5 mg and that occurred at a frequency greater than the placebo group in the 5 pooled trials are included in Table 1.</p>
<table frame="void" width="638">
<caption><span> Table 1. Adverse Reactions Reported by at Least 2% of Patients Treated With Naratriptan Tablets, USP and at a Frequency Greater Than Placebo</span></caption>
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Naratriptan Tablets,USP</span><span class="Bold"><br></span><span class="Bold">1 mg</span><span class="Bold">(n = 627)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold"> Naratriptan Tablets, USP </span><span class="Bold"><br></span><span class="Bold">2.5 mg</span><span class="Bold">(n = 627)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Placebo</span><span class="Bold">(n = 498)</span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Atypical sensation <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesias</span> (all types) </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">21</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">42</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">1&lt;1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Gastrointestinal <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">64</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">75</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">54</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Neurological <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">4112</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">7222</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">31&lt;11</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> and pressure sensation Throat/neck symptoms </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">21</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">42</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">21</td>
</tr>
</tbody>
</table>
<p>The incidence of adverse reactions in controlled clinical trials was not affected by age or weight of the patients, duration of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> prior to treatment, presence of <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>, use of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> medications, or tobacco use. There were insufficient data to assess the impact of race on the incidence of adverse reactions.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="b9c1a35b-5fb2-4abd-8884-901fac861899"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">7  DRUG INTERACTIONS 
</span></h1>
<div class="Section">
<a name="section-7.1"></a><p></p>
<h2><span class="Bold Italics">7.1 Ergot-Containing Drugs
</span></h2>
<p class="First">Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan tablets within 24 hours of each other is contraindicated.</p>
</div>
<div class="Section">
<a name="section-7.2"></a><p></p>
<h2><span class="Bold Italics">7.2 Other 5-HT<span class="Sub">1 </span>Agonists
</span></h2>
<p class="First">Concomitant use of other 5-HT<span class="Sub">1B/1D</span> agonists (including triptans) within 24 hours of treatment with naratriptan tablets is contraindicated because the risk of vasospastic reactions may be additive.</p>
</div>
<div class="Section">
<a name="bf355d08-471e-4f87-958b-c71d0684b5a6"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold Italics">7.3 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>
</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see <a href="#bcd2888d-39fa-4564-a766-f7f2fed08911">Warnings and Precautions (5.7)</a>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="bc7cbcc7-be82-427b-9308-d62c1d42b6ca"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">8  USE IN SPECIFIC POPULATIONS 
</span></h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42228-7">
<a name="bde21af0-e598-41ca-a32a-3e46381f1afd"></a><a name="section-8.1"></a><p></p>
<h2><span class="Bold Italics">8.1  PREGNANCY 
</span></h2>
<p class="First"><span class="Underline">Pregnancy Category C:</span> There are no adequate and well-controlled trials in pregnant women. Naratriptan tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>In reproductive toxicity studies in rats and rabbits, oral administration of naratriptan was associated with developmental toxicity (embryolethality, fetal abnormalities, pup mortality, offspring <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>) at doses producing maternal plasma drug exposures as low as 11 and 2.5 times, respectively, the exposure in humans receiving the maximum recommended daily dose (MRDD) of 5 mg.</p>
<p>When naratriptan was administered to pregnant rats during the period of organogenesis at doses of 10, 60, or 340 mg/kg/day, there was a dose-related increase in embryonic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>; incidences of fetal structural variations (incomplete/irregular ossification of skull bones, sternebrae, ribs) were increased at all doses. The maternal plasma exposures (AUC) at these doses were approximately 11, 70, and 470 times the exposure in humans at the MRDD. The high dose was maternally toxic, as evidenced by decreased maternal body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> during gestation. A no-effect dose for developmental toxicity in rats exposed during organogenesis was not established.</p>
<p>When naratriptan was administered orally (1, 5, or 30 mg/kg/day) to pregnant Dutch rabbits throughout organogenesis, the incidence of a specific fetal skeletal malformation (fused sternebrae) was increased at the high dose, and increased incidences of embryonic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and fetal variations (major blood vessel variations, supernumerary ribs, incomplete skeletal ossification) were observed at all doses (4, 20, and 120 times, respectively, the MRDD on a body surface area basis). Maternal toxicity (decreased body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>) was evident at the high dose in this study. In a similar study in New Zealand White rabbits (1, 5, or 30 mg/kg/day throughout organogenesis), decreased fetal weights and increased incidences of fetal skeletal variations were observed at all doses (maternal exposures equivalent to 2.5, 19, and 140 times exposure in humans receiving the MRDD), while maternal body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was reduced at 5 mg/kg or greater. A no-effect dose for developmental toxicity in rabbits exposed during organogenesis was not established.</p>
<p>When female rats were treated orally with naratriptan (10, 60, or 340 mg/kg/day) during late gestation and lactation, offspring behavioral impairment (<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>) and decreased offspring viability and growth were observed at doses of 60 mg/kg or greater, while maternal toxicity occurred only at the highest dose. Maternal exposures at the no-effect dose for developmental effects in this study were approximately 11 times the exposure in humans receiving the MRDD.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="bc8de804-fa47-461f-b5aa-4d873c8f766f"></a><a name="section-8.2"></a><p></p>
<h2><span class="Bold Italics"> 8.3  NURSING MOTHERS 
</span></h2>
<p class="First">Naratriptan is excreted in rat milk. It is not known whether naratriptan is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from naratriptan tablets, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2><span class="Bold Italics"> 8.4  PEDIATRIC USE 
</span></h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. Therefore, naratriptan tablets are not recommended for use in patients younger than18 years of age.</p>
<p>One controlled clinical trial evaluated naratriptan tablets (0.25 to 2.5 mg) in 300 adolescent migraineurs aged 12 to 17 years who received at least 1 dose of naratriptan tablets for an <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span>. In this study, 54% of the patients were female and 89% were Caucasian. There were no statistically significant differences between any of the treatment groups. The <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response rates at 4 hours (n) were 65% (n = 74), 67% (n = 78), and 64% (n = 70) for placebo, 1-mg, and 2.5-mg groups, respectively. This trial did not establish the efficacy of naratriptan tablets compared with placebo in the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> in adolescents. Adverse reactions observed in this clinical trial were similar in nature to those reported in clinical trials in adults.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="bedb8c50-aa04-447c-8614-858186f30ef7"></a><a name="section-8.4"></a><p></p>
<h2><span class="Bold Italics">8.5  GERIATRIC USE 
</span></h2>
<p class="First">Clinical trials of naratriptan tablets did not include sufficient numbers of patients aged 65 and older to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.</p>
<p>Naratriptan is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in elderly patients who have reduced renal function. In addition, elderly patients are more likely to have decreased hepatic function, they are at higher risk for CAD, and blood pressure increases may be more pronounced in the elderly.</p>
<p>A cardiovascular evaluation is recommended for geriatric patients who have other cardiovascular risk factors (e.g., <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, strong family history of CAD) prior to receiving naratriptan tablets [see <span class="Italics"><a href="#b178a942-f9f3-409c-8826-4d3d6ada91f2">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section">
<a name="b2d7fb9d-572a-4827-8ce0-a4d324f8987a"></a><a name="section-8.5"></a><p></p>
<h2><span class="Bold Italics">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</span></h2>
<p class="First">The use of naratriptan tablets is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance: &lt;15 mL/min) because of decreased clearance of the drug. In patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the recommended starting dose is 1 mg, and the maximum daily dose should not exceed 2.5 mg over a 24-hour period [see <span class="Italics"><a href="#bf8befc8-2137-47bc-850e-e048bdf234e2">Dosage and Administration (2.2)</a></span><span class="Italics">, </span><span class="Italics"><a href="#b9049735-f40c-4327-a642-7d1bd7fefcc6">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section">
<a name="b7691efe-5637-487c-bea4-f09e12a9ead0"></a><a name="section-8.6"></a><p></p>
<h2><span class="Bold Italics">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</span></h2>
<p class="First">The use of naratriptan tablets is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh grade C) because of decreased clearance. In patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh grade A or B), the recommended starting dose is 1 mg, and the maximum daily dose should not exceed 2.5 mg over a 24-hour period [see <span class="Italics"><a href="#b28be3d1-8900-4ba2-9339-69d25b55f1bd">Dosage and Administration (2.3)</a></span><span class="Italics">, </span><span class="Italics"><a href="#b9049735-f40c-4327-a642-7d1bd7fefcc6">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">10  OVERDOSAGE 
</span></h1>
<p class="First">Adverse reactions observed after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of up to 25 mg included increases in blood pressure resulting in <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, neck <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, and loss of coordination. Also, ischemic ECG changes likely due to coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> have been reported.</p>
<p>The elimination half-life of naratriptan  is about 6 hours [see <span class="Italics"><a href="#b9049735-f40c-4327-a642-7d1bd7fefcc6">Clinical Pharmacology (12.3)</a></span>], and therefore monitoring of patients after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with naratriptan tablets should continue for at least 24 hours or while symptoms or signs persist. There is no specific antidote to naratriptan. It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of naratriptan.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1><span class="Bold">11  DESCRIPTION 
</span></h1>
<p class="First">Naratriptan tablets, USP contain naratriptan hydrochloride, a selective 5-HT<span class="Sub">1B/1D</span> receptor agonist. Naratriptan hydrochloride is chemically designated as N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide monohydrochloride, and it has the following structure:</p>
<div class="Figure"><img alt="844387f0-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=41c29652-32f8-48dc-9038-0e2195aa2084&amp;name=844387f0-figure-01.jpg"></div>
<p>The empirical formula is C<span class="Sub">17</span>H<span class="Sub">25</span>N<span class="Sub">3</span>O<span class="Sub">2</span>S•HCl, representing a molecular weight of 371.93. Naratriptan hydrochloride is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow powder that is readily soluble in water. Each naratriptan tablet for oral administration contains 1.11 or 2.78 mg of naratriptan hydrochloride, equivalent to 1 or 2.5 mg of naratriptan, respectively. Each tablet also contains the inactive ingredients lactose anhydrous, microcrystalline cellulose, croscarmellose sodium, magnesium stearate. 1 mg tablet additionally contains opadry yellow, which contains: hypromellose 2910, titanium dioxide, polyethylene glycol 400 and iron oxide yellow. 2.5 mg tablet additionally contains opadry white, which contains: hypromellose 2910, talc, polyethylene glycol 8000 and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1><span class="Bold">12  CLINICAL PHARMACOLOGY 
</span></h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2><span class="Bold Italics"> 12.1  MECHANISM OF ACTION 
</span></h2>
<p class="First">Naratriptan binds with high affinity to human cloned 5-HT<span class="Sub">1B/1D</span> receptors. <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraines</span> are likely due to local cranial <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> and/or to the release of sensory neuropeptides (including substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of naratriptan for the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> is thought to be due to the agonist effects at the 5-HT<span class="Sub">1B/1D</span> receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2><span class="Bold Italics"> 12.2  PHARMACODYNAMICS 
</span></h2>
<p class="First">In the anesthetized dog, naratriptan has been shown to reduce the carotid arterial blood flow with little or no effect on arterial blood pressure or total peripheral resistance. While the effect on blood flow was selective for the carotid arterial bed, increases in <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> of up to 30% were seen in the coronary arterial bed. Naratriptan has also been shown to inhibit trigeminal nerve activity in rat and cat.</p>
<p>In 10 subjects with suspected CAD undergoing coronary artery catheterization, there was a 1% to 10% reduction in coronary artery diameter following subcutaneous injection of 1.5 mg of naratriptan [see <span class="Italics"><a href="#b19ca367-6d7c-4139-931a-e90635c34161">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="b9049735-f40c-4327-a642-7d1bd7fefcc6"></a><a name="section-11.3"></a><p></p>
<h2><span class="Bold Italics"> 12.3  PHARMACOKINETICS 
</span></h2>
<p class="First"><span class="Underline">Absorption:</span> Naratriptan is well absorbed, with about 70% oral bioavailability. Following administration of a 2.5-mg tablet, the peak concentrations are obtained in 2 to 3 hours. After administration of 1-or 2.5-mg tablets, the C<span class="Sub">max </span>is somewhat (about 50%) higher in women (not corrected for milligram-per-kilogram dose) than in men. During a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack, absorption is slower, with a T<span class="Sub">max</span> of 3 to 4 hours. Food does not affect the pharmacokinetics of naratriptan.</p>
<p>Naratriptan displays linear kinetics over the therapeutic dose range.</p>
<p><span class="Underline">Distribution: </span>The steady-state volume of distribution of naratriptan is 170 L. Plasma protein binding is 28% to 31% over the concentration range of 50 to 1,000 ng/mL.</p>
<p><span class="Underline">Metabolism:</span> In vitro, naratriptan is metabolized by a wide range of cytochrome P450 isoenzymes into a number of inactive metabolites.</p>
<p><span class="Underline">Elimination:</span> Naratriptan is predominantly eliminated in urine, with 50% of the dose recovered unchanged and 30% as metabolites in urine. The mean elimination half-life of naratriptan is 6 hours. The systemic clearance of naratriptan is 6.6 mL/min/kg. The renal clearance (220 mL/min) exceeds glomerular filtration rate, indicating active tubular secretion. Repeat administration of naratriptan tablets does not result in drug accumulation.</p>
<p><span class="Underline">Special Populations: </span></p>
<p><span class="Italics">Age: </span>A small decrease in clearance (approximately 26%) was observed in healthy elderly subjects (65 to 77 years) compared with younger subjects, resulting in slightly higher exposure [see <span class="Italics"><a href="#bedb8c50-aa04-447c-8614-858186f30ef7">Use in Specific Populations (8.5)</a></span>].</p>
<p><span class="Italics">Race:</span> The effect of race on the pharmacokinetics of naratriptan has not been examined.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Clearance of naratriptan was reduced by 50% in subjects with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance: 18 to 39 mL/min) compared with the normal group. Decrease in clearances resulted in an increase of mean half-life from 6 hours (healthy) to 11 hours (range: 7 to 20 hours). The mean Cmax increased by approximately 40%. The effects of severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance: ≤ 15 mL/min) on the pharmacokinetics of naratriptan have not been assessed [see <span class="Italics"><a href="#b19ca367-6d7c-4139-931a-e90635c34161">Contraindications (4)</a></span>].</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Clearance of naratriptan was decreased by 30% in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh grade A or B). This resulted in an approximately 40% increase in the half-life (range: 8 to 16 hours). The effects of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh grade C) on the pharmacokinetics of naratriptan have not been assessed [see <span class="Italics"><a href="#b19ca367-6d7c-4139-931a-e90635c34161">Contraindications</a></span> (4)].</p>
<p><span class="Underline">Drug Interaction Studies:</span> From population pharmacokinetic analyses, co-administration of naratriptan and fluoxetine, beta-blockers, or tricyclic antidepressants did not affect the clearance of naratriptan.</p>
<p><span class="Italics">Oral Contraceptives:</span> Oral contraceptives reduced clearance by 32% and volume of distribution by 22%, resulting in slightly higher concentrations of naratriptan. Hormone replacement therapy had no effect on pharmacokinetics in older female patients.</p>
<p><span class="Italics">Monoamine Oxidase and P450 Inhibitors:</span> Naratriptan does not inhibit monoamine oxidase (MAO) enzymes and is a poor inhibitor of P450; metabolic interactions between naratriptan and drugs metabolized by P450 or MAO are therefore unlikely.</p>
<p><span class="Italics">Smoking:</span> Smoking increased the clearance of naratriptan by 30%.</p>
<p><span class="Italics">Alcohol: </span>In normal volunteers, co-administration of single doses of naratriptan tablets and alcohol did not result in substantial modification of naratriptan pharmacokinetic parameters.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1><span class="Bold">13  NONCLINICAL TOXICOLOGY 
</span></h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2><span class="Bold Italics"> 13.1  CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY 
</span></h2>
<p class="First"><span class="Underline">Carcinogenesis: </span>In carcinogenicity studies, mice and rats were given naratriptan by oral gavage for 104 weeks. There was no evidence of an increase in tumors related to naratriptan administration in mice receiving up to 200 mg/kg/day. That dose was associated with a plasma (AUC) exposure that was 110 times the exposure in humans receiving the maximum recommended daily dose (MRDD) of 5 mg. Two rat studies were conducted, one using a standard diet and the other a nitrite-supplemented diet (naratriptan can be nitrosated in vitro to form a mutagenic product that has been detected in the stomachs of rats fed a high-nitrite diet). Doses of 5, 20, and 90 mg/kg were associated with AUC exposures that in the standard-diet study were 7, 40, and 236 times, respectively, and in the nitrite-supplemented–diet study were 7, 29, and 180 times, respectively, the exposure in humans at the MRDD. In both studies, there was an increase in the incidence of thyroid follicular <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in high-dose males and females and in thyroid follicular <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in high-dose males. In the standard-diet study only, there was also an increase in the incidence of benign c-cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in the thyroid of high-dose males and females. The exposures achieved at the no-effect dose for <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumors</span> were 40 (standard diet) and 29 (nitrite-supplemented diet) times the exposure achieved in humans at the MRDD. In the nitrite-supplemented diet study only, the incidence of benign lymphocytic thymoma was increased in all treated groups of females. It was not determined if the nitrosated product is systemically absorbed. However, no changes were seen in the stomachs of rats in that study.</p>
<p><span class="Underline">Mutagenesis: </span>Naratriptan was not mutagenic when tested in in vitro gene mutation (Ames and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> <span class="Italics">tk</span>) assays. Naratriptan was also negative in the in vitro human lymphocyte assay and the in vivo mouse micronucleus assay. Naratriptan can be nitrosated in vitro to form a mutagenic product (WHO nitrosation assay) that has been detected in the stomachs of rats fed a nitrite-supplemented diet.</p>
<p><span class="Underline">Impairment of Fertility:</span> In a reproductive toxicity study in which male and female rats were administered naratriptan orally prior to and throughout the mating period (10, 60, 170, or 340 mg/kg/day; plasma exposures [AUC] approximately 11, 70, 230, and 470 times, respectively, the human exposure at the MRDD), there was a treatment-related decrease in the number of females exhibiting normal estrous cycles at doses of 170 mg/kg/day or greater and an increase in preimplantation loss at 60 mg/kg/day or greater. In high-dose males, testicular/epididymal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> accompanied by spermatozoa depletion reduced mating success and may have contributed to the observed preimplantation loss. The exposures achieved at the no-effect doses for preimplantation loss, anestrus, and testicular effects were approximately 11, 70, and 230 times, respectively, the exposures in humans at the MRDD.</p>
<p>In a study in which rats were dosed orally with naratriptan (10, 60, or 340 mg/kg/day) for 6 months, changes in the female reproductive tract including atrophic or cystic ovaries and anestrus were seen at the high dose. The exposure at the no-effect dose of 60 mg/kg was approximately 85 times that in humans at the MRDD.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1><span class="Bold">14  CLINICAL STUDIES 
</span></h1>
<p class="First">The efficacy of naratriptan tablets in the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> was evaluated in 3 randomized, double-blind, placebo-controlled trials in adult patients (Trials 1, 2, 3). These trials enrolled adult patients who were predominantly female (86%) and Caucasian (96%) with a mean age of 41 years (range: 18 to 65 years). In all studies, patients were instructed to treat at least 1 moderate to severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> response, defined as a reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> severity from moderate or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> to mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, was assessed up to 4 hours after dosing. Associated symptoms such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> were also assessed. Maintenance of response was assessed for up to 24 hours postdose. A second dose of naratriptan tablets or other rescue medication to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> was allowed 4 to 24 hours after the initial treatment for recurrent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>In all 3 trials, the percentage of patients achieving <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response 4 hours after treatment, the primary outcome measure, was significantly greater among patients receiving naratriptan tablets compared with those who received placebo. In all trials, response to 2.5 mg was numerically greater than response to 1 mg and in the largest of the 3 trials, there was a statistically significant greater percentage of patients with <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response at 4 hours in the 2.5-mg group compared</p>
<table frame="void" width="638">
<caption><span> Table 2. Percentage of Adult Patients With <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response (Mild or No <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>) 4 Hours Following Treatment</span></caption>
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Naratriptan Tablets, USP 1 mg</span><span class="Bold">(n =491)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Naratriptan Tablets, USP 2.5 mg</span><span class="Bold">(n = 493) </span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo</span><span class="Bold">(n = 395)</span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Trial 1</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">50%<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">60%<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">34%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Trial 2</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">52%<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">66%<span class="Sup">ab</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">27%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Trial 3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">54%<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">65%<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">32%</td>
</tr>
<tr><td class="Toprule" align="left" colspan="4" valign="middle">
<span class="Sup">a</span><span class="Italics">P</span>&lt;0.05 compared with placebo.</td></tr>
<tr class="Last"><td align="left" colspan="4" valign="middle">
<span class="Sup">b</span><span class="Italics">P</span>&lt;0.05 compared with 1 mg. </td></tr>
</tbody>
</table>
<p>The estimated probability of achieving an initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response in adults over the 4 hours following treatment in pooled Trials 1, 2, and 3 is depicted in Figure 1.</p>
<p><span class="Bold">Figure 1. Estimated Probability of Achieving Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response Within 4 Hours in Pooled Trials 1, 2, and 3</span><span class="Bold"><span class="Sup">a</span></span></p>
<div class="Figure"><img alt="844387f0-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=41c29652-32f8-48dc-9038-0e2195aa2084&amp;name=844387f0-figure-02.jpg"></div>
<p><span class="Sup">a</span> The figure shows the probability over time of obtaining <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response (reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> severity from moderate or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> to no or mild <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) following treatment with naratriptan tablets, USP. In this Kaplan-Meier plot, patients not achieving response within 240 minutes were censored at 240 minutes.</p>
<p>For patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> at baseline, there was a lower incidence of these symptoms 4 hours following administration of 1-mg and 2.5-mg naratriptan tablets, USP compared with placebo.</p>
<p>Four to 24 hours following the initial dose of study treatment, patients were allowed to use additional treatment for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief in the form of a second dose of study treatment or other rescue medication. The estimated probability of patients taking a second dose or other rescue medication to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> over the 24 hours following the initial dose of study treatment is summarized in Figure 2.</p>
<p><span class="Bold">Figure 2. Estimated Probability of Patients Taking a Second Dose of Naratriptan Tablets, USP or Other Medication to Treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Trials 1, 2 and 3</span><span class="Bold"><span class="Sup">a</span></span></p>
<div class="Figure"><img alt="844387f0-figure-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=41c29652-32f8-48dc-9038-0e2195aa2084&amp;name=844387f0-figure-03.jpg"></div>
<p><span class="Sup">a</span> Kaplan-Meier plot based on data obtained in the 3 controlled clinical trials (Trials 1, 2, and 3) providing evidence of efficacy with patients not using additional treatments censored at 24 hours.</p>
<p>The plot also includes patients who had no response to the initial dose. Remedication was discouraged prior to 4 hours postdose.</p>
<p>There is no evidence that doses of 5 mg provided a greater effect than 2.5 mg. There was no evidence to suggest that treatment with naratriptan tablets was associated with an increase in the severity or frequency of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. The efficacy of naratriptan tablets was unaffected by presence of <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>; gender, age, or weight of the subject; oral contraceptive use; or concomitant use of common <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> drugs (e.g., beta-blockers, calcium channel blockers, tricyclic antidepressants). There was insufficient data to assess the impact of race on efficacy.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1><span class="Bold">16  HOW SUPPLIED /STORAGE AND HANDLING 
</span></h1>
<p class="First">Naratriptan tablets, USP containing 1 mg and 2.5 mg of naratriptan (base) as the hydrochloride.</p>
<p>Naratriptan tablets, USP 1 mg, are yellow, round, biconvex film-coated tablets, debossed with ‘I53’ on one side and plain on the other side in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 9 tablets (NDC 23155-054-19), in HDPE container packs of 30 tablets (NDC 23155-054-03), and 500 tablets (23155-054-05).</p>
<p>Naratriptan tablets, USP 2.5 mg, are white, ‘D’ shaped, biconvex film-coated tablets, debossed with ‘I54’ on one side and plain on the other side in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 9 tablets (23155-055-19), in HDPE container packs of 30 tablets (NDC 23155-055-03), and 500 tablets (NDC 23155-055-05).</p>
<p><span class="Bold">Store at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature].</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1><span class="Bold">17  PATIENT COUNSELING INFORMATION 
</span></h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Patient Information).</p>
<p><span class="Underline"> Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span>, Prinzmetal’s Angina, Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span>-Related Events, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, and Cerebrovascular Events: </span>Inform patients that naratriptan tablets may cause serious cardiovascular side effects such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. Although serious cardiovascular events can occur without warning symptoms, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, irregular heartbeat, significant <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and slurring of speech and should ask for medical advice if any indicative sign or symptoms are observed. Apprise patients of the importance of this follow-up [see <span class="Italics"><a href="#b02e42e6-f8fd-4d3b-8fb0-6ad65cf7a731">Warnings and Precautions</a></span> (5.1, 5.2, 5.4, 5.5, 5.8)].</p>
<p><span class="Underline">Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span>:</span> Inform patients that anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients receiving naratriptan tablets. Such reactions can be life threatening or fatal. In general, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens [see <span class="Italics"><a href="#b19ca367-6d7c-4139-931a-e90635c34161">Contraindications</a></span> (4), <span class="Italics"><a href="#b02e42e6-f8fd-4d3b-8fb0-6ad65cf7a731">Warnings and Precautions </a></span>(5.9)].</p>
<p><span class="Underline">Concomitant Use With Other Triptans or Ergot Medications:</span> Inform patients that use of naratriptan tablets within 24 hours of another triptan or an ergot-type medication (including dihydroergotamine or methysergide) is contraindicated [see <span class="Italics"><a href="#b19ca367-6d7c-4139-931a-e90635c34161">Contraindications (4)</a></span><span class="Italics">, </span><span class="Italics"><a href="#b9c1a35b-5fb2-4abd-8884-901fac861899">Drug Interactions</a></span> (7.1, 7.2)].</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>:</span> Caution patients about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the use of naratriptan tablets or other triptans, particularly during combined use with SSRIs, SNRIs, TCAs, and MAO inhibitors [see <span class="Italics"><a href="#bcd2888d-39fa-4564-a766-f7f2fed08911">Warnings and Precautions</a></span> (5.7), <span class="Italics"><a href="#bf355d08-471e-4f87-958b-c71d0684b5a6">Drug Interactions</a></span> (7.3)].</p>
<p><span class="Underline">Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>:</span> Inform patients that use of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> drugs for 10 or more days per month may lead to an exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and encourage patients to record <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> frequency and drug use (e.g., by keeping a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> diary) [see <span class="Italics"><a href="#b3ae15d0-095c-44c0-9170-bd5664ef96a1">Warnings and Precautions (5.6)</a></span>].</p>
<p><span class="Underline">Pregnancy:</span> Inform patients that naratriptan tablets should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus [see <span class="Italics"><a href="#bde21af0-e598-41ca-a32a-3e46381f1afd">Use in Specific Populations (8.1)</a></span>].</p>
<p><span class="Underline">Nursing Mothers: </span>Advise patients to notify their healthcare provider if they are breastfeeding or plan to breastfeed [see <span class="Italics"><a href="#bc8de804-fa47-461f-b5aa-4d873c8f766f">Use in Specific Populations (8.3)</a></span>].</p>
<p><span class="Underline">Ability to Perform Complex Tasks: </span>Treatment with naratriptan tablets may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; instruct patients to evaluate their ability to perform complex tasks after administration of naratriptan tablets.</p>
<p>Manufactured for:</p>
<p><span class="Bold">Heritage Pharmaceuticals Inc. </span></p>
<p>Eatontown, NJ 07724</p>
<p>1.866.901. DRUG (3784)</p>
<p>Made in India.</p>
<p>Revised: 10/13</p>
<p><span class="Bold">Patient Information </span><span class="Bold"><br></span><span class="Bold">NARATRIPTAN TABLETS, USP</span></p>
<p>Read this Patient Information before you start taking naratriptan tablets and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment.</p>
<p><span class="Bold">What is the most important information I should know about naratriptan tablets? </span></p>
<p><span class="Bold">Naratriptan tablets can cause serious side effects, including: </span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> and other heart problems. Heart problems may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span></p>
<p><span class="Bold">Stop taking naratriptan tablets and get emergency medical help right away if you have any of the following symptoms of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>: </span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in the center of your chest that lasts for more than a few minutes, or that goes away and comes back</li>
<li>severe tightness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, pressure, or heaviness in your chest, throat, neck, or jaw</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in your arms, back, neck, jaw, or stomach</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> with or without <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span></li>
<li>breaking out in a <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">cold sweat</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>feeling lightheaded</li>
</ul>
<p>Naratriptan tablets are not for people with risk factors for heart disease unless a heart exam is done and shows no problem. You have a higher risk for heart disease if you:</p>
<ul class="Disc">
<li>have high blood pressure</li>
<li>have high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels</li>
<li>smoke</li>
<li>are overweight</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li>have a family history of heart disease</li>
</ul>
<p><span class="Bold">What are naratriptan tablets? </span></p>
<p>Naratriptan tablets is a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> headaches with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults who have been diagnosed with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>.</p>
<p>Naratriptan tablets are not used to prevent or decrease the number of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> you have.</p>
<p>Naratriptan tablets are not used to treat other types of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> such as hemiplegic <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> (that make you unable to move on one side of your body) or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> (rare form of <span class="product-label-link" type="condition" conceptid="381549" conceptname="Migraine with aura">migraine with aura</span>).</p>
<p>It is not known if naratriptan tablets are safe and effective to treat <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headaches</span>.</p>
<p>It is not known if naratriptan tablets are safe and effective in children under 18 years of age.</p>
<p><span class="Bold">Who should not take naratriptan tablets? </span></p>
<p><span class="Bold">Do not take naratriptan tablets if you have: </span></p>
<ul class="Disc">
<li>heart problems or a history of heart problems</li>
<li>narrowing of blood vessels to your legs, arms, stomach, or kidney (<span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>)</li>
<li>uncontrolled high blood pressure</li>
<li>severe kidney problems</li>
<li>severe liver problems</li>
<li>hemiplegic <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>. If you are not sure if you have these types of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>, ask your healthcare provider.</li>
<li>had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span> (TIAs), or problems with your blood circulation</li>
<li>taken any of the following medicines in the last 24 hours:</li>
<li>almotriptan (AXERT<span class="Sup">®</span>)</li>
<li>eletriptan (RELPAX<span class="Sup">®</span>)</li>
<li>frovatriptan (FROVA<span class="Sup">®</span>)</li>
<li>rizatriptan (MAXALT<span class="Sup">®</span>, MAXALT-MLT<span class="Sup">®</span>)</li>
<li>sumatriptan (IMITREX<span class="Sup">®</span>, SUMAVEL<span class="Sup">®</span> DosePro<span class="Sup">®</span>, ALSUMA<span class="Sup">®</span>)</li>
<li>sumatriptan and naproxen (TREXIMET<span class="Sup">®</span>)</li>
<li>ergotamines (CAFERGOT<span class="Sup">®</span>, ERGOMAR<span class="Sup">®</span>, MIGERGOT<span class="Sup">®</span> )</li>
<li>dihydroergotamine (D.H.E. 45<span class="Sup">®</span>, MIGRANAL<span class="Sup">®</span>)</li>
</ul>
<p>Ask your healthcare provider if you are not sure if your medicine is listed above.</p>
<ul class="Disc">
<li>an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to naratriptan or any of the ingredients in naratriptan tablets. See the end of this leaflet for a complete list of ingredients in naratriptan tablets.<p class="First"><span class="Bold">What should I tell my healthcare provider before taking naratriptan tablets? </span></p>
<p>Before you take naratriptan tablets, tell your healthcare provider about all of your medical conditions, including if you:</p>
</li>
<li>have high blood pressure</li>
<li>have high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li>smoke</li>
<li>are overweight</li>
<li>have heart problems or family history of heart problems or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>have kidney problems</li>
<li>have liver problems</li>
<li>are not using effective birth control</li>
<li>become pregnant while taking naratriptan tablets</li>
<li>are breastfeeding or plan to breastfeed. It is not known if naratriptan tablets passes into your breast milk. Talk with your healthcare provider about the best way to feed your baby if you take naratriptan tablets.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take</span>, including prescription and nonprescription medicines, vitamins, and herbal supplements.</p>
<p>Using naratriptan tablets with certain other medicines can affect each other, causing serious side effects.</p>
<p><span class="Bold">Especially tell your healthcare provider if</span> you take anti-depressant medicines</p>
<p>called:</p>
<ul class="Disc">
<li>selective serotonin reuptake inhibitors (SSRIs)</li>
<li>serotonin norepinephrine reuptake inhibitors (SNRIs)</li>
<li>tricyclic antidepressants (TCAs)</li>
<li>monoamine oxidase inhibitors (MAOIs)</li>
</ul>
<p>Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take naratriptan tablets? </span></p>
<ul class="Disc">
<li>Certain people should take their first dose of naratriptan tablets in their healthcare provider’s office or in another medical setting. Ask your healthcare provider if you should take your first dose in a medical setting.</li>
<li>Take naratriptan tablets exactly as your healthcare provider tells you to take it.</li>
<li>Your healthcare provider may change your dose. Do not change your dose without first talking with your healthcare provider.</li>
<li>Take naratriptan tablets with water or other liquids.</li>
<li>If you do not get any relief after your first naratriptan tablet, do not take a second tablet without first talking with your healthcare provider.</li>
<li>If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> comes back or you only get some relief from your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, you can take a second tablet 4 hours after the first tablet.</li>
<li>Do not take more than a total of 5 mg of naratriptan tablets in a 24-hour period.</li>
<li>Some people who take too many naratriptan tablets may have worse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> (medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>). If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> get worse, your healthcare provider may decide to stop your treatment with naratriptan tablets.</li>
<li>If you take too much naratriptan tablets, call your healthcare provider or go to the nearest hospital emergency room right away.</li>
<li>You should write down when you have <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> and when you take naratriptan tablets so you can talk with your healthcare provider about how naratriptan tablets is working for you.</li>
</ul>
<p><span class="Bold">What should I avoid while taking naratriptan tablets? </span></p>
<p>Naratriptan tablets can cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. If you have these symptoms, do not drive a car, use machinery, or do anything where you need to be alert.</p>
<p><span class="Bold">What are the possible side effects of naratriptan tablets? </span></p>
<p><span class="Bold">Naratriptan tablets may cause serious side effects.</span> See “What is the most important information I should know about naratriptan tablets??</p>
<p>These serious side effects include:</p>
<ul class="Disc">
<li>changes in color or sensation in your fingers and toes (Raynaud’s syndrome)</li>
<li>stomach and intestinal problems (gastrointestinal and colonic ischemic events). Symptoms of gastrointestinal and colonic ischemic events include:</li>
<li>sudden or severe <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> after meals</li>
<li><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li>problems with blood circulation to your legs and feet (peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>). Symptoms of peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> include:</li>
<li>cramping and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your legs or hips</li>
<li>feeling of heaviness or tightness in your leg muscles</li>
<li>burning or aching <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your feet or toes while resting</li>
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in your legs</li>
<li><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> feeling or color changes in 1 or both legs or feet</li>
<li>medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>. Some people who use too many naratriptan tablets may have worse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> (medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>). If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> get worse, your healthcare provider may decide to stop your treatment with naratriptan tablets.</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> is a rare but serious problem that can happen in people using naratriptan tablets, especially if naratriptan tablets are used with anti-depressant medicines called SSRIs, SNRIs, TCAs, or MAOIs. Call your healthcare provider right away if you have any of the following symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>:</li>
<li>mental changes such as seeing things that are not there (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>), <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span></li>
<li>fast heartbeat</li>
<li>changes in blood pressure</li>
<li>high body temperature</li>
<li>tight muscles</li>
<li>trouble walking</li>
</ul>
<p>The most common side effects of naratriptan tablets include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in your fingers or toes</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li>warm, hot, burning feeling to your face (<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> or <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> in your neck</li>
<li>feeling weak, drowsy, or tired</li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of naratriptan tablets. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to Heritage Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store naratriptan tablets? </span></p>
<p>Store naratriptan tablets between 20°C and 25°C (68°F and 77°F). <span class="Bold">[See USP Controlled Room Temperature]</span></p>
<p><span class="Bold">Keep naratriptan tablets and all medicines out of the reach of children. </span></p>
<p><span class="Bold">General information about the safe and effective use of naratriptan tablets. </span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use naratriptan tablets for a condition for which it was not prescribed. Do not give naratriptan tablets to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Patient Information leaflet summarizes the most important information about naratriptan tablets. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about naratriptan tablets that is written for healthcare professionals.</p>
<p>For more information, call 1-866-901-DRUG (3784).</p>
<p><span class="Bold">What are the ingredients in naratriptan tablets? </span></p>
<p>Active ingredient: naratriptan hydrochloride</p>
<p>Inactive ingredients: lactose anhydrous, microcrystalline cellulose, croscarmellose sodium, magnesium stearate.</p>
<p>1 mg tablet additionally contains opadry yellow, which contains: hypromellose 2910, titanium dioxide, polyethylene glycol 400 and iron oxide yellow.</p>
<p>2.5 mg tablet additionally contains opadry white, which contains: hypromellose 2910, talc, polyethylene glycol 8000 and titanium dioxide.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>The brands listed are registered trademarks of their respective owners.</p>
<p><span class="Bold">Manufactured for:</span></p>
<p>Heritage Pharmaceuticals Inc.</p>
<p>Eatontown, NJ 07724</p>
<p>1.866.901.DRUG  (3784)</p>
<p>Made in India.</p>
<p>Revised: 10/13</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<p class="First"><span class="Bold">Naratriptan Tablets, USP 1 mg, 9-unit of use tablets</span></p>
<div class="Figure"><img alt="844387f0-figure-04" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=41c29652-32f8-48dc-9038-0e2195aa2084&amp;name=844387f0-figure-04.jpg"></div>
<p><span class="Bold">Naratriptan Tablets, USP 1 mg, 30-count bottle</span></p>
<div class="Figure"><img alt="844387f0-figure-05" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=41c29652-32f8-48dc-9038-0e2195aa2084&amp;name=844387f0-figure-05.jpg"></div>
<p><span class="Bold">Naratriptan Tablets, USP 2.5 mg, 9-unit of use tablets</span></p>
<div class="Figure"><img alt="844387f0-figure-06" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=41c29652-32f8-48dc-9038-0e2195aa2084&amp;name=844387f0-figure-06.jpg"></div>
<p><span class="Bold">Naratriptan Tablets, USP 2.5 mg, 30-count bottle</span></p>
<div class="Figure"><img alt="844387f0-figure-07" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=41c29652-32f8-48dc-9038-0e2195aa2084&amp;name=844387f0-figure-07.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NARATRIPTAN 		
					</strong><br><span class="contentTableReg">naratriptan tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:23155-054</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NARATRIPTAN HYDROCHLORIDE</strong> (NARATRIPTAN) </td>
<td class="formItem">NARATRIPTAN</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">I53</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:23155-054-19</td>
<td class="formItem">9  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:23155-054-03</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:23155-054-05</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200502</td>
<td class="formItem">03/15/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NARATRIPTAN 		
					</strong><br><span class="contentTableReg">naratriptan tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:23155-055</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NARATRIPTAN HYDROCHLORIDE</strong> (NARATRIPTAN) </td>
<td class="formItem">NARATRIPTAN</td>
<td class="formItem">2.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (D shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">I54</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:23155-055-19</td>
<td class="formItem">9  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:23155-055-03</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:23155-055-05</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200502</td>
<td class="formItem">03/15/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Heritage Pharmaceuticals Inc.
							(780779901)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">USV Limited</td>
<td class="formItem"></td>
<td class="formItem">650434348</td>
<td class="formItem">MANUFACTURE(23155-054, 23155-055)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>844387f0-c48c-4302-8626-0a12bba8fe33</div>
<div>Set id: 41c29652-32f8-48dc-9038-0e2195aa2084</div>
<div>Version: 8</div>
<div>Effective Time: 20131025</div>
</div>
</div> <div class="DistributorName">Heritage Pharmaceuticals Inc.</div></p>
</body></html>
